PATENT CLAIM ANALYSIS

Application Number: 16125317
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "133100"]

Abstract:
Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.

Claim (Index 36):
The isolated antibody according to  claim 35 , wherein the Fc region comprises the amino acid substitutions C11S, C14S, P23S and further comprises the amino acid substitution C5S.

Metadata:
- Claim Count in Document: 92.0
- Percentile: 97.0
- Lexical Diversity: 1.05
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15667477', '12532517', '14309118', '11871136', '13656922']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7569365694841694
- 35 USC 102 Novelty (BERT): 0.6241283840896177
- Combined Prediction Score: 0.7436557509447143
- Mean Citation Score: 432.208416
- Max Citation Score: 687.2389
- Similarity Product: 482.3378006806433

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test